Evidence map›Paper›PMID 38097606›Full record

ArticleNature communications2023

Proximity extracellular protein-protein interaction analysis of EGFR using AirID-conjugated fragment of antigen binding.

Kohdai Yamada, Ryouhei Shioya, Kohei Nishino, Hirotake Furihata, Atsushi Hijikata, Mika K Kaneko, Yukinari Kato, Tsuyoshi Shirai, Hidetaka Kosako, Tatsuya Sawasaki

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Kohdai YamadaDivision of Cell-Free Life Science, Proteo-Science Center, Ehime University, 3 Bunkyo-cho, Matsuyama, Ehime, 790-8577, Japan.
Ryouhei ShioyaDivision of Cell-Free Life Science, Proteo-Science Center, Ehime University, 3 Bunkyo-cho, Matsuyama, Ehime, 790-8577, Japan.
Kohei NishinoDivision of Cell Signaling, Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, 770-8503, Japan.
Hirotake FurihataDivision of Cell-Free Life Science, Proteo-Science Center, Ehime University, 3 Bunkyo-cho, Matsuyama, Ehime, 790-8577, Japan.ORCID 0000-0002-0171-6751
Atsushi HijikataLaboratory of Computational Genomics, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Hachioji, 192-0392, Japan.
Mika K KanekoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, 980-8575, Japan.ORCID 0000-0002-4158-9208
Yukinari KatoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, 980-8575, Japan.ORCID 0000-0001-5385-8201
Tsuyoshi ShiraiDepartment of Bioscience, Nagahama Institute of BioScience and Technology, 1266 Tamura, Nagahama, 526-0829, Japan.ORCID 0000-0002-2506-5738
Hidetaka KosakoDivision of Cell Signaling, Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, 770-8503, Japan. kosako@tokushima-u.ac.jp.ORCID 0000-0003-3228-6368
Tatsuya SawasakiDivision of Cell-Free Life Science, Proteo-Science Center, Ehime University, 3 Bunkyo-cho, Matsuyama, Ehime, 790-8577, Japan. sawasaki@ehime-u.ac.jp.ORCID 0000-0002-7952-0556
Ehime University · JPTohoku University · JPTokushima University · JPNagahama Institute of Bio-Science and Technology · JPTokyo University of Pharmacy and Life Sciences · JP

Funding

Japan Agency for Medical Research and Development (AMED) 22ama121010j0001Japan Agency for Medical Research and Development (AMED) 23ama121010j0002Japan Agency for Medical Research and Development (AMED) JP21am0101077Japan Agency for Medical Research and Development (AMED) JP22ama121008MEXT | Japan Society for the Promotion of Science (JSPS) 19H03218MEXT | Japan Society for the Promotion of Science (JSPS) JP21K19230
6 · The paper itself

Abstract

Receptor proteins, such as epidermal growth factor receptor (EGFR), interact with other proteins in the extracellular region of the cell membrane to drive intracellular signalling. Therefore, analysis of extracellular protein-protein interactions (exPPIs) is important for understanding the biological function of receptor proteins. Here, we present an approach using a proximity biotinylation enzyme (AirID) fusion fragment of antigen binding (FabID) to analyse the proximity exPPIs of EGFR. AirID was C-terminally fused to the Fab fragment against EGFR (EGFR-FabID), which could then biotinylate the extracellular region of EGFR in several cell lines. Liquid Chromatography-Mass Spectrometry (LC-MS/MS) analysis indicated that many known EGFR interactors were identified as proximity exPPIs, along with many unknown candidate interactors, using EGFR-FabID. Interestingly, these proximity exPPIs were influenced by treatment with EGF ligand and its specific kinase inhibitor, gefitinib. These results indicate that FabID provides accurate proximity exPPI analysis of target receptor proteins on cell membranes with ligand and drug responses.

Indexed as

ErbB ReceptorsTandem Mass SpectrometryChromatography, LiquidEpidermal Growth FactorLigandsPhosphorylationEpidermal Growth FactorErbB ReceptorsLigands

Identifiers

PMID38097606
PMCPMC10721602
OpenAlexW4389738380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.